Idiopathic pulmonary arterial hypertension: current state of play and new treatment modalities

Int J Cardiol. 2004 Dec:97 Suppl 1:7-10. doi: 10.1016/j.ijcard.2004.08.003.

Abstract

Research in pulmonary hypertension has led to exciting advances over the last decade, both in terms of understanding aetiology and expanding treatment options. This review highlights the current approach to classification and disease management. In particular, we review the significant data and recommendations on the use of prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors and drug combinations.

Publication types

  • Review

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Calcium Channel Blockers / therapeutic use
  • Cardiac Catheterization
  • Environment
  • Genetic Predisposition to Disease
  • Humans
  • Hypertension, Pulmonary / classification
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / therapy*
  • Mutation
  • Vasoconstrictor Agents / therapeutic use
  • Vasodilator Agents / therapeutic use

Substances

  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Vasoconstrictor Agents
  • Vasodilator Agents